{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:59:39Z","timestamp":1788242379479,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":3261,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin-like growth factor 1 (IGF-1) and improves insulin sensitivity in cats with HS when administered as a short-acting preparation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Assess once-monthly administration of long-acting pasireotide (pasireotide LAR) for treatment of cats with HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fourteen cats with HS, diagnosed based on diabetes mellitus, pituitary enlargement, and serum IGF-1 &amp;gt; 1000 ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Uncontrolled, prospective cohort study. Cats received pasireotide LAR (6\u20138 mg\/kg SC) once monthly for 6 months. Fructosamine and IGF-1 concentrations, and 12-hour blood glucose curves (BGCs) were assessed at baseline and then monthly. Product of fructosamine concentration and insulin dose was calculated as an indicator of insulin resistance (Insulin Resistance Index). Linear mixed-effects modeling assessed for significant change in fructosamine, IGF-1, mean blood glucose (MBG) of BGCs, insulin dose (U\/kg) and Insulin Resistance Index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight cats completed the trial. Three cats entered diabetic remission. Median IGF-1 (baseline: 1962 ng\/mL [range 1051\u20132000 ng\/mL]; month 6: 1253 ng\/mL [524\u20131987 ng\/mL]; P &amp;lt; .001) and median Insulin Resistance Index (baseline: 812 \u03bcmolU\/L kg [173\u20133565 \u03bcmolU\/L kg]; month 6: 135 \u03bcmolU\/L kg [0\u2013443 \u03bcmolU\/L kg]; P = .001) decreased significantly. No significant change was found in mean fructosamine (baseline: 494 \u00b1 127 \u03bcmol\/L; month 6: 319 \u00b1 113.3 \u03bcmol\/L; P = .07) or MBG (baseline: 347.7 \u00b1 111.0 mg\/dL; month 6: 319.5 \u00b1 113.3 mg\/dL; P = .11), despite a significant decrease in median insulin dose (baseline: 1.5 [0.4\u20135.2] U\/kg; 6 months: 0.3 [0.0\u20131.4] U\/kg; P &amp;lt; .001). Adverse events included diarrhea (n = 11), hypoglycemia (n = 5), and worsening polyphagia (n = 2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Pasireotide LAR is the first drug to show potential as a long-term management option for cats with HS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14662","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:13:18Z","timestamp":1485907998000},"page":"355-364","source":"Crossref","is-referenced-by-count":35,"title":["Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism"],"prefix":"10.1093","volume":"31","author":[{"given":"R.","family":"Gostelow","sequence":"first","affiliation":[{"name":"Diabetic Remission Clinic , Department of Clinical Science and Services, Royal Veterinary College, Hertfordshire,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scudder","sequence":"additional","affiliation":[{"name":"Diabetic Remission Clinic , Department of Clinical Science and Services, Royal Veterinary College, Hertfordshire,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Keyte","sequence":"additional","affiliation":[{"name":"Diabetic Remission Clinic , Department of Clinical Science and Services, Royal Veterinary College, Hertfordshire,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Forcada","sequence":"additional","affiliation":[{"name":"Diabetic Remission Clinic , Department of Clinical Science and Services, Royal Veterinary College, Hertfordshire,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C.","family":"Fowkes","sequence":"additional","affiliation":[{"name":"Royal Veterinary College Department of Comparative Biomedical Sciences, , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Schmid","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Oncology Research, Novartis Pharma AG , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Church","sequence":"additional","affiliation":[{"name":"Diabetic Remission Clinic , Department of Clinical Science and Services, Royal Veterinary College, Hertfordshire,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.M.","family":"Niessen","sequence":"additional","affiliation":[{"name":"Diabetic Remission Clinic , Department of Clinical Science and Services, Royal Veterinary College, Hertfordshire,","place":["UK"]},{"name":"Newcastle Medical School , Newcastle upon Tyne,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"2026020922042921800_jvim14662-bib-0001","article-title":"Evaluation of insulin-like growth factor-1, total thyroxine, feline pancreas-specific lipase and urinary corticoid-to-creatinine ratio in cats with diabetes mellitus in Switzerland and the Netherlands","author":"Schaefer","year":"2016","journal-title":"J Feline Med Surg"},{"key":"2026020922042921800_jvim14662-bib-0002","doi-asserted-by":"crossref","first-page":"e0127794","DOI":"10.1371\/journal.pone.0127794","article-title":"Studying cat (Felis catus) diabetes: Beware of the acromegalic imposter","volume":"10","author":"Niessen","year":"2015","journal-title":"PLoS ONE"},{"key":"2026020922042921800_jvim14662-bib-0003","first-page":"37","article-title":"Canine and Feline Endocrinology","author":"Reusch","year":"2015","edition":"4"},{"key":"2026020922042921800_jvim14662-bib-0004","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1939-1676.2007.tb03041.x","article-title":"Feline acromegaly: An underdiagnosed endocrinopathy?","volume":"21","author":"Niessen","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020922042921800_jvim14662-bib-0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/mp.54.5.311","article-title":"Insulin-like growth factor 1 (IGF-1): A growth hormone","volume":"54","author":"Laron","year":"2001","journal-title":"Mol Pathol"},{"key":"2026020922042921800_jvim14662-bib-0006","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jvim.12386","article-title":"Echocardiographic findings in 11 cats with acromegaly","volume":"28","author":"Myers","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2026020922042921800_jvim14662-bib-0007","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1939-1676.1990.tb00897.x","article-title":"Acromegaly in 14 cats","volume":"4","author":"Peterson","year":"1990","journal-title":"J Vet Intern Med"},{"key":"2026020922042921800_jvim14662-bib-0008","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020922042921800_jvim14662-bib-0009","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jfms.2010.03.014","article-title":"Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy","volume":"12","author":"Meij","year":"2010","journal-title":"J Feline Med Surg"},{"key":"2026020922042921800_jvim14662-bib-0010","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4158\/EP15913.RA","article-title":"Historical response rates of somatostatin analogs in the treatment of acromegaly: A systematic review","volume":"22","author":"Shanik","year":"2016","journal-title":"Endocr Pract"},{"key":"2026020922042921800_jvim14662-bib-0011","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11318510-000000000-00000","article-title":"Medical therapy of acromegaly: Efficacy and safety of somatostatin analogues","volume":"69","author":"Feelders","year":"2009","journal-title":"Drugs"},{"key":"2026020922042921800_jvim14662-bib-0012","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.domaniend.2008.07.004","article-title":"Growth hormone excess and the effect of octreotide in cats with diabetes mellitus","volume":"35","author":"Slingerland","year":"2008","journal-title":"Domest Anim Endocrinol"},{"key":"2026020922042921800_jvim14662-bib-0013","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1751-0813.2002.tb12469.x","article-title":"Treatment of an acromegalic cat with the dopamine agonist L-deprenyl","volume":"80","author":"Abraham","year":"2002","journal-title":"Aust Vet J"},{"key":"2026020922042921800_jvim14662-bib-0014","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000079048","article-title":"Somatostatin receptors in pituitary function, diagnosis and therapy","volume":"32","author":"Hofland","year":"2004","journal-title":"Front Horm Res"},{"key":"2026020922042921800_jvim14662-bib-0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2026020922042921800_jvim14662-bib-0016","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"key":"2026020922042921800_jvim14662-bib-0017","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026020922042921800_jvim14662-bib-0018","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/jvim.12608","article-title":"Pasireotide for the medical management of feline hypersomatotropism","volume":"29","author":"Scudder","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020922042921800_jvim14662-bib-0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0034-5288(94)90101-5","article-title":"Effects of proligestone and megestrol on plasma adrenocorticotrophic hormone, insulin and insulin-like growth factor-1 concentrations in cats","volume":"56","author":"Church","year":"1994","journal-title":"Res Vet Sci"},{"key":"2026020922042921800_jvim14662-bib-0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1098612X13497212","article-title":"Computed tomographic signs of acromegaly in 68 diabetic cats with hypersomatotropism","volume":"16","author":"Lamb","year":"2014","journal-title":"J Feline Med Surg"},{"key":"2026020922042921800_jvim14662-bib-0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1740-8261.2005.00006.x","article-title":"Dynamic computed tomography of the normal feline hypophysis cerebri (Glandula pituitaria)","volume":"46","author":"Tyson","year":"2005","journal-title":"Vet Radiol Ultrasound"},{"key":"2026020922042921800_jvim14662-bib-0022","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1098612X12469523","article-title":"Ultrasonographic appearance of adrenal glands in healthy and sick cats","volume":"15","author":"Combes","year":"2013","journal-title":"J Feline Med Surg"},{"key":"2026020922042921800_jvim14662-bib-0023","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cvsm.2012.12.004","article-title":"Hypersomatotropism, acromegaly, and hyperadrenocorticism and feline diabetes mellitus","volume":"43","author":"Niessen","year":"2013","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020922042921800_jvim14662-bib-0024","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: A head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026020922042921800_jvim14662-bib-0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1939-1676.2008.0242.x","article-title":"Exogenous insulin treatment after hypofractionated radiotherapy in cats with diabetes mellitus and acromegaly","volume":"23","author":"Dunning","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020922042921800_jvim14662-bib-0026","first-page":"258","article-title":"Canine and Feline Endocrinology","author":"Reusch","year":"2015","edition":"4"},{"key":"2026020922042921800_jvim14662-bib-0027","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-2007-976541","article-title":"Insulin sensitivity and beta-cell function in healthy cats: Assessment with the use of the hyperglycemic glucose clamp","volume":"39","author":"Slingerland","year":"2007","journal-title":"Horm Metab Res"},{"key":"2026020922042921800_jvim14662-bib-0028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcpa.2003.09.004","article-title":"Somatotroph and corticotroph pituitary adenoma (double adenoma) in a cat with diabetes mellitus and hyperadrenocorticism","volume":"130","author":"Meij","year":"2004","journal-title":"J Comp Pathol"},{"key":"2026020922042921800_jvim14662-bib-0029","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11102-015-0677-y","article-title":"The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"key":"2026020922042921800_jvim14662-bib-0030","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026020922042921800_jvim14662-bib-0031","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","article-title":"Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5","volume":"57","author":"Zambre","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"2026020922042921800_jvim14662-bib-0032","article-title":"Signifor LAR Safety Profile","author":"Novartis"},{"key":"2026020922042921800_jvim14662-bib-0033","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/jcph.326","article-title":"Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I study","volume":"54","author":"Petersenn","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2026020922042921800_jvim14662-bib-0034","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2036.2000.014s2039.x","article-title":"Review: Pathogenesis of gallstones","volume":"14","author":"Dowling","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2026020922042921800_jvim14662-bib-0035","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0016-5085(94)90556-8","article-title":"The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones","volume":"107","author":"Hussaini","year":"1994","journal-title":"Gastroenterology"},{"key":"2026020922042921800_jvim14662-bib-0036","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/eje.1.02213","article-title":"Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours","volume":"155","author":"Hubina","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2026020922042921800_jvim14662-bib-0037","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","article-title":"Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression","volume":"66","author":"Theodoropoulou","year":"2006","journal-title":"Cancer Res"},{"key":"2026020922042921800_jvim14662-bib-0038","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0165-6147(00)88992-0","article-title":"Multiple actions of somatostatin in neoplastic disease","volume":"16","author":"Reubi","year":"1995","journal-title":"Trends Pharmacol Sci"},{"key":"2026020922042921800_jvim14662-bib-0039","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11102-007-0044-8","article-title":"Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging","volume":"10","author":"Sathyapalan","year":"2007","journal-title":"Pituitary"},{"key":"2026020922042921800_jvim14662-bib-0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1179\/174313208X289499","article-title":"Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: Special reference to the octreotide treatment","volume":"30","author":"Kurosaki","year":"2008","journal-title":"Neurol Res"},{"key":"2026020922042921800_jvim14662-bib-0041","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: A long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026020922042921800_jvim14662-bib-0042","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI2908","article-title":"Regulatory mechanisms of growth hormone secretion are sexually dimorphic","volume":"102","author":"Jaffe","year":"1998","journal-title":"J Clin Invest"},{"key":"2026020922042921800_jvim14662-bib-0043","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: A meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026020922042921800_jvim14662-bib-0044","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clpt.2005.04.003","article-title":"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly","volume":"78","author":"Ma","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"2026020922042921800_jvim14662-bib-0045","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1939-1676.2007.tb03040.x","article-title":"Serum insulin-like growth factor-I concentration in cats with diabetes mellitus and acromegaly","volume":"21","author":"Berg","year":"2007","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.14662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.14662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/2\/355\/66668948\/jvim14662.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/2\/355\/66668948\/jvim14662.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:06:19Z","timestamp":1770692779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/31\/2\/355\/8449456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14662","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,3]]},"published":{"date-parts":[[2017,3,1]]}}}